عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Renewable Energy Project in Yemen to Benefit over 62,000 Yemenis

Using Renewable Energy to Improve Quality of Life Project Concludes in Yemen with Benefiting over 62,000 Yemenis. (SPA)
Using Renewable Energy to Improve Quality of Life Project Concludes in Yemen with Benefiting over 62,000 Yemenis. (SPA)
TT
TT

Renewable Energy Project in Yemen to Benefit over 62,000 Yemenis

Using Renewable Energy to Improve Quality of Life Project Concludes in Yemen with Benefiting over 62,000 Yemenis. (SPA)
Using Renewable Energy to Improve Quality of Life Project Concludes in Yemen with Benefiting over 62,000 Yemenis. (SPA)

Yemeni Prime Minister Maeen Abdulmalik attended in Aden the closing ceremony of the Using Renewable Energy to Improve Quality of Life Project, which was implemented with a trilateral partnership of the Saudi Development and Reconstruction Program for Yemen (SDRPY), Arab Gulf Program for Development (AGFUND), and Selah Foundation for Development, SPA said on Wednesday.
The project has benefited 62,000 people in five Yemeni governorates of Hadhramaut, Abyan, Lahij, Taiz and Al-Hudaydah.
During the ceremony, Yemeni Minister of Social Affairs and Labor Mohamad Al-Zaouri praised the generous support of the government of Saudi Arabia, through the SDRPY, AGFUND, and Selah Foundation for Development, for holding vital projects that affect citizens' lives and contribute to improving their standard of life.
He stressed that this support contributes to achieving sustainable development in the country.
The project significantly contributes to enhancing health and education facilities by efficiently meeting their energy needs in a sustainable manner. It supports the operation of critical medical equipment, creates conducive educational environments for students and teachers, and provides sustainable and accessible energy to targeted families through the installation of home appliance systems.
Moreover, this initiative aims to uplift the standard of living in Yemen by improving beneficiaries' daily lives, fostering economic development through increased agricultural production, bolstering food security for Yemenis, reducing carbon emissions to protect the environment, and establishing a clean, sustainable energy source.
The venture involves the rehabilitation of 12 drinking water wells using solar energy systems, provisioning of 35 renewable-energy-based agricultural irrigation systems, powering 20 educational and health facilities, and delivering renewable energy to 133 homes across five Yemeni governorates—Hadhramaut, Abyan, Lahij, Taiz, and Al-Hudaydah.
Project activities encompass comprehensive training courses tailored for field engineers. These courses focus on implementing solar energy systems, aiming to enhance the skills of field technical teams and fortify their technical capacities. The project's substantial contributions to society address numerous water-related challenges, such as interruptions and accessibility issues. The training curriculum covers a wide array of technical and administrative aspects.

Most Viewed

 
 
Varieties

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”